Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELGN-2112 in Preterm and IUGR Infants
NCT05904626Phase 2Recruiting
- Sponsor
- Elgan Pharma
- Start
- Oct 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in intestinal malabsorption comparing ELGN-2112 with Placebo (2 arms). Primary endpoints: Safety of treatment with ELGN-2112 in preterm infants <26 weeks GA at 42 days and Safety of treatment with ELGN-2112 in IUGR infants 26-32 weeks GA at 42 days. Started Oct 2025; status: recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on NCT05904626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05904626.